ARVN
PFE
RIGL
New deal, new runway
Rigel Pharmaceuticals is suddenly in the driver’s seat on a pretty intriguing breast cancer asset. The company says it’s entering an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU, also known as vepdegestrant, a PROTAC drug aimed at ER+/HER2- ESR1-mutated advanced or metastatic breast cancer.
Why investors care
This isn’t just biotech jargon with a fancy acronym sprinkled on top. Rigel plans to help fund development with up to $40 million over the next four years, and in exchange it gets a crack at launching the drug in the U.S. and pursuing global rights. That’s the kind of move that can completely change the math for a small biotech if the drug keeps delivering.
The pitch here is simple:
- the Phase 3 VERITAC-2 data showed a meaningful progression-free survival win versus fulvestrant
- the drug was described as generally well tolerated
- Rigel sees a path to future revenue, not just another press release to pin to the fridge
The catch, because biotech loves a catch
The article also says the FDA approved vepdegestrant in May 2026, but it doesn’t give a specific approval date. If that approval holds, it removes a major overhang and makes the licensing deal even more interesting. If you’re an investor, the big question is whether Rigel can turn a promising oncology asset into actual cash flow instead of just another slide deck hero.
Big picture: Rigel just bought itself a much bigger story. Whether that story becomes a commercial win depends on execution, but the market is clearly treating this like more than science fair hype.